ODC1 and colorectal carcinoma: COXs, ODC, and HMG Co-A reductase are the most validated targets for CRC tertiary prevention, and their inhibitors (NSAIDs, COXibs, and statins) showed promising efficacy in the reduction of adenocarcinoma based on pre-clinical and clinical evaluations [40,123,124,125,126,127].